146388-91-2

Upstream product

• 146369-88-2 (5S,6S)-6-(tert-butoxycarbonyl)amino-7-cyclohexyl-2-methyl-5-hydroxy-3-heptanone 
• 563-80-4 3-methyl-butan-2-one 
• 17510-45-1 2-(trimethylsilyloxy)-3-methyl-1-butene 

Downstream Products

• 146682-53-3 (2S,3S,5S)-2-amino-1-cyclohexyl-6-methyl-3,5-heptanediol 
• 146682-56-6 (S)-N-((1S,2S,4S)-1-Cyclohexylmethyl-2,4-dihydroxy-5-methyl-hexyl)-3-(1H-imidazol-4-yl)-2-methylamino-propionamide 
• 198989-75-2 [(S)-1-((1S,2S,4S)-1-Cyclohexylmethyl-2,4-dihydroxy-5-methyl-hexylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-methyl-carbamic acid benzyl ester 
• 198989-67-2 1,4-Dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid ((S)-1-{[(S)-1-((1S,2S,4S)-1-cyclohexylmethyl-2,4-dihydroxy-5-methyl-hexylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-methyl-carbamoyl}-2-phenyl-ethyl)-amide 

Relevant academic research and scientific papers

Diastereoselective aldol reaction of an α-alkoxycarbonylamino aldehyde with a silyl enol ether

The aldol reaction of optically active α-alkoxycarbonylamino aldehydes with a silyl enol ether in the presence of a Lewis acid afforded γ-amino-β- hydroxyketones diastereoselectively. The effect of the α-amide proton on the diastereoselectivity is discussed.

Novel renin inhibitors containing (2S,3S,5S)-2-amino-1-cyclohexyl-6- methyl-3,5-heptanediol fragment as a transition-state mimic at the P1-P1' cleavage site

A series of renin inhibitors containing the (2S,3S,5S)-2-amino-1- cyclohexyl-6-methyl-3,5-heptanediol (2-amino-3,5-anti-diol) fragment as a novel transition-state mimic was synthesized, and their biological activities were evaluated. All of the synthesized compounds containing the 2-amino-3,5- anti-diol fragment at the P1-P1' position showed high in vitro renin- inhibitory activity with IC50 values in the 10-8-10-10 M range, and most of them caused a reduction of blood pressure when administered orally to salt-depleted, conscious marmosets. The inhibitor (29) with the 4- hydroxypiperidine residue at the P4 position showed the highest activity in terms of both potency and duration of the blood pressure-lowering effect.